Taxotere (Breast Cancer) Analysis and Forecats to 2017


#28311

47pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Taxotere (Breast Cancer) Analysis and Forecasts to 2017 provides Taxotere sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2017). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Taxotere including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Taxotere including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2017 for Taxotere in the seven major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Report Guidance 7


3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 9
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 10
3.3.4 Decreasing Breast Cancer Mortality Rate 12
3.3.5 High Survival Rates of Breast Cancer 15


4 Staging of Breast Cancer: Introduction 16
4.1 Distribution of Patients by Stages 16
4.1.1 Stages 16


5 Predictive Biomarker in the Treatment of Breast Cancer 19


6 Treatment options of Breast Cancer 21
6.1 Stage 0 Breast Cancer: Treatment Options 21
6.2 Early Stage Breast Cancer (Excluding Stage 0) 22
6.3 Metastatic Breast Cancer (MBC) 24
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 24
6.3.2 Cytotoxic Chemotherapy 26
6.3.3 Management of Patients with HER-2 Positive Patients 28


7 Taxotere 30
7.1 Introduction 30
7.2 Mechanism of Action 30
7.3 Clinical Studies 30
7.3.1 As a Treatment in Locally Advanced and Metastatic Breast Cancer in Comparison with Mitomycin and Vinblastine 30
7.3.2 Taxotere in Combination with Doxorubicin and Cyclophosphamide for the Adjuvant Treatment of Patients with Axillary-Node-Positive Breast Cancer 31
7.4 Approval History of Taxotere 31
7.5 Factors Affecting Sales of Taxotere 31
7.5.1 High Efficacy 31
7.5.2 Deaths Related to High Toxicity 32
7.5.3 Indicated for Large Patient Pool 32
7.5.4 Patent Expiry 32
7.6 Drug Risk Benefit Score 32
7.6.1 Efficacy 32
7.6.2 Safety 32
7.6.3 Compliance 33
7.6.4 Dosing Convenience 33
7.7 Intensity of Competition 33
7.8 Sales Forecasts 33
7.8.1 Target Patient Pool of Taxotere 33
7.8.2 Dosing 34
7.8.3 Market Penetration 34
7.8.4 Annual Cost of Therapy 34
7.8.5 Sales Projections of Taxotere 35


8 Appendix 43
8.1 Market Definitions 43
8.2 Abbreviations 43
8.3 Research Methodology 43
8.3.1 Coverage 44
8.3.2 Secondary Research 44
8.3.3 Forecasting 44
8.3.4 Number of Patients Approved to take the Drug 44
8.3.5 Net Penetration of Drug 45
8.3.6 Net Annual Dosing 46
8.3.7 Annual Cost of Therapy 46
8.3.8 Primary Research 46
8.3.9 Expert Panels 46
8.4 Contact Us 47
8.5 Disclaimer 47
8.6 Sources 47

 

Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5

Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020 9

Table 3: Five-Year Relative Survival Rates, By Stages 15

Table 4: Study Details 30

Table 5: Taxotere Approval History 31

Table 6: Drug Risk Benefit Score (DRB Score) 32

Table 7: Drug Comparison 33

Table 8: Annual Cost of Taxotere for Localized Stage in 2009 34

Table 9: Annual Cost of Taxotere for Advanced Stages in 2009 35

Table 10: Taxotere, Breast Cancer, Global, Sales Estimates($m), 2002-2017 35

Table 11: Taxotere, Breast Cancer, the US, Sales Estimates ($m), 2002-2015 36

Table 12: Taxotere, Breast Cancer, the UK, Sales Estimates($m), 2002-2015 37

Table 13: Taxotere, Breast Cancer, France, Sales Estimates($m), 2002-2015 38

Table 14: Taxotere, Breast Cancer, Germany, Sales Estimates($m), 2002-2015 39

Table 15: Taxotere, Breast Cancer, Italy, Sales Estimates($m), 2002-2015 40

Table 16: Taxotere, Breast Cancer, Spain, Sales Estimates($m), 2002-2015 41

Table 17: Taxotere, Breast Cancer, Japan, Sales Estimates($m), 2002-2017 42


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Top 10 Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 10
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 12
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 12
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 13
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 13
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 14
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 14
Figure 12: Broad Classification of Breast Cancer, By Type 16
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 16
Figure 14: Classification of Invasive Breast Cancer, By Stages 17
Figure 15: Classification of Invasive Breast Cancer, By Treatment 17
Figure 16: Classification of Metastatic or Advanced Breast Cancer 17
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 18
Figure 18: Classification of Locally Advanced Breast Cancer 18
Figure 19: Metastatic Breast Cancer Classification 18
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 19
Figure 21: Breast Cancer Intrinsic Sub Types used for deciding Treatment Options for MBC 20
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 20
Figure 23: Treatment Options, DCIS Breast Cancer 21
Figure 24: Treatment Options, LCIS Breast Cancer 22
Figure 25: Treatment Options, Stages I, II and IIIA 22
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 23
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 23
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 24
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 25
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 25
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 27
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 28
Figure 33: Target Patient Pool of Taxotere 33
Figure 34: Taxotere, Breast Cancer, Global, Sales Estimates($m), 2002-2017 35
Figure 35: Taxotere, Breast Cancer, the US, Sales Estimates($m), 2002-2015 36
Figure 36: Taxotere, Breast Cancer, the UK, Sales Estimates($m), 2002-2015 36
Figure 37: Taxotere, Breast Cancer, France, Sales Estimates($m), 2002-2015 37
Figure 38: Taxotere, Breast Cancer, Germany, Sales Estimates($m), 2002-2015 39
Figure 39: Taxotere, Breast Cancer, Italy, Sales Estimates($m), 2002-2015 40
Figure 40: Taxotere, Breast Cancer, Spain, Sales Estimates($m), 2002-2015 41
Figure 41: Taxotere, Breast Cancer, Japan, Sales Estimates($m), 2002-2017 42
Figure 42: Drug Model Diagram 45
Figure 43: Patients Approved to take the Drug 46